SEC Comment Letter 0000000000-24-012425 to C4 Therapeutics, Inc. (CCCC) (CIK 0001662579) (CCCC)

C4 Therapeutics, Inc. (CCCC) (CIK 0001662579)
Date: Nov. 7, 2024 · CIK: 0001662579 · Accession: 0000000000-24-012425

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-282934

Date

November 7, 2024

Author

Division of

Form

UPLOAD

Company

C4 Therapeutics, Inc. (CCCC) (CIK 0001662579)

Letter

Re: C4 Therapeutics, Inc. Registration Statement on Form S-3 Filed October 31, 2024 File No. 333-282934 Dear Andrew J. Hirsch:

November 7, 2024

Andrew J. Hirsch President and Chief Executive Officer C4 Therapeutics, Inc. 490 Arsenal Way, Suite 120 Watertown, Massachusetts 02472

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tim Buchmiller at 202-551-3635 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Shoaib A. Ghias, Esq.

Show Raw Text

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
                                                           November 7, 2024

Andrew J. Hirsch
President and Chief Executive Officer
C4 Therapeutics, Inc.
490 Arsenal Way, Suite 120
Watertown, Massachusetts 02472

       Re: C4 Therapeutics, Inc.
           Registration Statement on Form S-3
           Filed October 31, 2024
           File No. 333-282934
Dear Andrew J. Hirsch:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Tim Buchmiller at 202-551-3635 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:   Shoaib A. Ghias, Esq.
</TEXT>
</DOCUMENT>

SecProbe.io